BINAXNOW™ MALARIA

With malaria, a life could depend on the ability to make an accurate differential diagnosis.

Aids in the diagnosis of *Plasmodium falciparum* infection versus pan-malarial infection caused by *Plasmodium vivax, Plasmodium ovale* or *Plasmodium malariae*.
MALARIA: KEY FACTS

The Asia-Pacific region accounts for nearly 70% of the burden outside the World Health Organisation (WHO) African region. The prevalence of *P. falciparum* and *P. vivax* varies by country but on average is around 60% and 40%, respectively. Within this region, India and Indonesia accounted for 80% and 16% of the reported cases and 60% and 30% of malaria deaths in 2016, respectively.¹

---

**3.3 BILLION**

Almost half the world is at risk of malaria. In 2016, the African region was home to 90% of malaria cases.¹

---

**216 MILLION**

Cases in 2016, compared to 211 million cases in 2015.¹

---

**445,000**

Deaths in 2016. Of these, roughly two-thirds were children under 5 years of age.¹²

---

As per WHO recommendation, all cases of suspected malaria need to be confirmed by diagnostic testing prior to providing treatment.³

---

**BINAXNOW™ MALARIA**

**TOTAL TIME: 15 MINUTES**

Obtain blood

Add blood and reagent to card

Close card and read results in 15 minutes
For fast, qualitative detection of antigens to four species of malaria: 
*P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale*

**RAPID**
- Results seen in 15 minutes, enabling immediate treatment

**EASY TO USE**
- Simple-to-use test using only one reagent
- Requires just a small blood sample easily collected by fingerprick
- No need for skilled microscopist

**EASY TO INTERPRET**
- Differentiated results that aid in the diagnosis of lethal *P. falciparum* infection
- Objective, qualitative results
- No subjective assessment required

**ACCURATE AND RELIABLE**
- High specificity and sensitivity
- Built-in procedural control ensures test viability
- Reduces unnecessary use of antimalarial drugs, thereby helping to minimise the development of drug-resistant malaria strains
BinaxNOW™ Malaria Test

HIGHLY SENSITIVE AND SPECIFIC FOR DETECTION OF MALARIA INFECTION

1. Apply 15 μL of blood to the purple pad. Ensure the entire pad is covered.

2. Apply 2 drops of reagent to the white pad immediately below where the blood was applied.

3. Apply 4 drops of reagent to the pad located at the top of the left-hand side of the test card after the blood runs up the full length of the test strip.

4. When the blood sample reaches the base of the white absorbent pad at the top of the test strip, close the device and read the results.

Procedure shown is for a capillary blood sample. For complete Instructions for Use, see the Package Insert.

READING RESULTS

<table>
<thead>
<tr>
<th>FINGERSTICK SAMPLES</th>
<th>% Sensitivity</th>
<th>95% CI</th>
<th>% Specificity</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. f.</td>
<td>98.8%</td>
<td>94%–100%</td>
<td>90.4%</td>
<td>88%–92%</td>
</tr>
<tr>
<td>P. v.</td>
<td>80.6%</td>
<td>73%–87%</td>
<td>99.5%</td>
<td>99%–100%</td>
</tr>
</tbody>
</table>

PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>ORDER NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>BinaxNOW™ Malaria Test</td>
<td>66005</td>
</tr>
<tr>
<td>5 Test Kit</td>
<td></td>
</tr>
<tr>
<td>BinaxNOW™ Malaria Test</td>
<td>660-000</td>
</tr>
<tr>
<td>25 Test Kit</td>
<td></td>
</tr>
</tbody>
</table>

OTHER BINAXNOW™ TESTS

- BinaxNOW™ Influenza A & B (NOT AVAILABLE IN THE UNITED STATES)
- BinaxNOW™ Legionella
- BinaxNOW™ RSV
- BinaxNOW™ S. Pneumoniae
- BinaxNOW™ Strep A
- BinaxNOW™ G6PD
- Alere Filariasis (NOT AVAILABLE IN THE UNITED STATES)

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. 12001428-03 08/20